NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD
1.94
-0.16 (-7.62%)
The current stock price of EVAX is 1.94 USD. In the past month the price decreased by -21.46%. In the past year, price decreased by -88.55%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.66 | 369.39B | ||
AMGN | AMGEN INC | 15.54 | 165.43B | ||
GILD | GILEAD SCIENCES INC | 24.8 | 142.43B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1654.45 | 123.26B | ||
REGN | REGENERON PHARMACEUTICALS | 15.31 | 76.39B | ||
ARGX | ARGENX SE - ADR | 242.12 | 37.96B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.83B | ||
ONC | BEIGENE LTD-ADR | N/A | 29.00B | ||
BNTX | BIONTECH SE-ADR | N/A | 27.07B | ||
NTRA | NATERA INC | N/A | 20.54B | ||
BIIB | BIOGEN INC | 8.53 | 20.47B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.26B |
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. The firm decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
EVAXION BIOTECH A/S
Bredgade 34E, Copenhagen K
COPENHAGEN 1260 DK
CEO: Lars Staal Webner
Employees: 49
Company Website: https://www.evaxion-biotech.com/
The current stock price of EVAX is 1.94 USD. The price decreased by -7.62% in the last trading session.
The exchange symbol of EVAXION BIOTECH A/S is EVAX and it is listed on the Nasdaq exchange.
EVAX stock is listed on the Nasdaq exchange.
8 analysts have analysed EVAX and the average price target is 47.37 USD. This implies a price increase of 2341.56% is expected in the next year compared to the current price of 1.94. Check the EVAXION BIOTECH A/S stock analysts ratings, price target forecast and up-and down grades for more detailed information.
EVAXION BIOTECH A/S (EVAX) has a market capitalization of 12.16M USD. This makes EVAX a Nano Cap stock.
EVAXION BIOTECH A/S (EVAX) currently has 49 employees.
EVAXION BIOTECH A/S (EVAX) has a resistance level at 2.05. Check the full technical report for a detailed analysis of EVAX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
EVAX does not pay a dividend.
EVAXION BIOTECH A/S (EVAX) will report earnings on 2025-03-25, after the market close.
EVAXION BIOTECH A/S (EVAX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.9).
ChartMill assigns a fundamental rating of 1 / 10 to EVAX. EVAX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months EVAX reported a non-GAAP Earnings per Share(EPS) of -0.9. The EPS increased by 90.53% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -99.83% | ||
ROE | -1213.49% | ||
Debt/Equity | 7.99 |
ChartMill assigns a Buy % Consensus number of 83% to EVAX. The Buy consensus is the average rating of analysts ratings from 8 analysts.